Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Soria, Gali ^a   Ofri Shahak, Maya ^a   Haas, Ilana ^a   Yaal Hahoshen, Neora ^a   Leider Trejo, Leonor ^a   Leibovich Rivkin, Tal ^a   Weitzenfeld, Polina ^a   Meshel, Tsipi ^a   Shabtai, Esther ^a   Gutman, Mordechai ^a   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER PATIENT; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TUMOR CELL; ADULT; BREAST TUMOR; CELL MOTION; CONFOCAL MICROSCOPY; DRUG EFFECT; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL2; CHEMOKINE CCL5; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953904617     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-130     Document Type: Article

References (84)

1. Lewis CE, Hughes R. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res 2007, 9(3):209. 10.1186/bcr1679, 1929095, 17601353.
2. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007, 67(11):5064-5066. 10.1158/0008-5472.CAN-07-0912, 17545580.
3. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008, 267(2):271-285. 10.1016/j.canlet.2008.03.018, 18439751.
4. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010, 11(9):1133-1146. 10.2174/138945010792006799, 20545607.
5. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 2006, 25(3):357-371. 10.1007/s10555-006-9003-5, 17016763.
6. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004, 14(3):149-154. 10.1016/j.semcancer.2003.10.009, 15246049.
7. Soria G, Ben-Baruch A. The CCL5/CCR5 axis in cancer. Springer Publishers, .
8. Pinilla S, Alt E, Abdul Khalek FJ, Jotzu C, Muehlberg F, Beckmann C, Song YH. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett 2009, 284(1):80-85. 10.1016/j.canlet.2009.04.013, 19427114.
9. Zhang Y, Yao F, Yao X, Yi C, Tan C, Wei L, Sun S. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 2009, 21(4):1113-1121. 10.3892/or_00000312, 19288016.
10. Lu X, Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 2009, 284(42):29087-29096. 10.1074/jbc.M109.035899, 2781454, 19720836.
11. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, Ochiai A. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 2009, 125(6):1276-1284. 10.1002/ijc.24378, 19479998.
12. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T, Kerin MJ. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007, 13(17):5020-5027. 10.1158/1078-0432.CCR-07-0731, 17785552.
13. Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, O'Brien T, Kerin MJ. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 2009, 124(2):326-332. 10.1002/ijc.23939, 19003962.
14. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449(7162):557-563. 10.1038/nature06188, 17914389.
15. Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I, Ben-Baruch A. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 2006, 12(15):4474-4480. 10.1158/1078-0432.CCR-06-0074, 16899591.
16. Soria G, Ben-Baruch A. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: A basis for tumor-promoting interactions. Cytokine 2008, 44:191-200. 10.1016/j.cyto.2008.08.002, 18790652.
17. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 1998, 194(5):335-340.
18. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001, 92(5):1085-1091. 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K, 11571719.
19. Goede V, Brogelli L, Ziche M, Augustin HG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999, 82(5):765-770. 10.1002/(SICI)1097-0215(19990827)82:5<765::AID-IJC23>3.0.CO;2-F, 10417778.
20. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, Ben-Baruch A. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999, 59(18):4681-4687.
21. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96(1):34-40.
22. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003, 63(23):8360-8365.
23. Stormes KA, Lemken CA, Lepre JV, Marinucci MN, Kurt RA. Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat 2005, 89(2):209-212. 10.1007/s10549-004-5328-3, 15692764.
24. Adler EP, Lemken CA, Katchen NS, Kurt RA. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 2003, 90(2-3):187-194. 10.1016/j.imlet.2003.09.013, 14687724.
25. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006, 25(3):409-416. 10.1007/s10555-006-9005-3, 16951987.
26. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, et al. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 2006, 42(6):751-759. 10.1016/j.ejca.2006.01.010, 16530403.
27. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006, 17(5):325-337. 10.1016/j.cytogfr.2006.07.002, 16931107.
28. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al. Expression of interleukin-1beta in human breast carcinoma. Cancer 1997, 80(3):421-434. 10.1002/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z, 9241076.
29. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006, 4:48. 10.1186/1479-5876-4-48, 1660548, 17096856.
30. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Lindquist R, Barrows G, Kreutzer DL. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest 2000, 18(4):293-302. 10.3109/07357900009012171, 10808364.
31. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Barrows G, Kreutzer DL. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 2003, 23(2):269-284.
32. Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M, Lindquist RR, Barrows G, Kreutzer DL. Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. Oncol Rep 1999, 6(1):65-70.
33. Pusztai L, Clover LM, Cooper K, Starkey PM, Lewis CE, McGee JO. Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. Br J Cancer 1994, 70(2):289-292. 10.1038/bjc.1994.294, 2033509, 7519867.
34. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994, 56(6):777-782. 10.1002/ijc.2910560603, 8119765.
35. Basolo F, Conaldi PG, Fiore L, Calvo S, Toniolo A. Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma. Int J Cancer 1993, 55(6):926-930. 10.1002/ijc.2910550609, 8253529.
36. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998, 77(12):2246-2251. 10.1038/bjc.1998.373, 2150409, 9649140.
37. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci 2006, 97(10):1044-1049. 10.1111/j.1349-7006.2006.00277.x, 16984377.
38. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997, 43(3):211-215. 10.1023/A:1005736712307, 9150900.
39. Cui LF, Guo XJ, Wei J, Liu FF, Gu F, Fan Y, Lang RG, Fu L. [Significance of interleukin-1beta expression and microvascular density in invasive micropapillary carcinoma of breast]. Zhonghua Bing Li Xue Za Zhi 2008, 37(9):599-603.
40. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 2005, 16(4):253-260.
41. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007, 9(1):R15. 10.1186/bcr1648, 1851386, 17261184.
42. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006, 42(6):745-750. 10.1016/j.ejca.2006.01.012, 16517151.
43. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Chouchane L. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 2001, 91(4):672-678. 10.1002/1097-0142(20010215)91:4<672::AID-CNCR1050>3.0.CO;2-J, 11241233.
44. Mestiri S, Bouaouina N, Ben Ahmed S, Chouchane L. A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma. Cytokine 2005, 30(4):182-187. 10.1016/j.cyto.2005.01.007, 15863392.
45. Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, Artac M, Altunbas H, Akan I, Savas B. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004, 27(2-3):58-65. 10.1016/j.cyto.2004.04.002, 15242694.
46. Rubio MF, Werbajh S, Cafferata EG, Quaglino A, Colo GP, Nojek IM, Kordon EC, Nahmod VE, Costas MA. TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene 2006, 25(9):1367-1377. 10.1038/sj.onc.1209176, 16331275.
47. Seeger H, Wallwiener D, Mueck AO. Different effects of estradiol and various antiestrogens on TNF-alpha-induced changes of biochemical markers for growth and invasion of human breast cancer cells. Life Sci 2006, 78(13):1464-1468. 10.1016/j.lfs.2005.07.042, 16253280.
48. Sirotkovic-Skerlev M, Cacev T, Krizanac S, Kulic A, Pavelic K, Kapitanovic S. TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp Mol Pathol 2007, 83(1):54-58. 10.1016/j.yexmp.2006.11.004, 17234183.
49. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, et al. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res 2008, 314(3):509-529. 10.1016/j.yexcr.2007.10.005, 18061162.
50. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004, 25(8):1543-1549. 10.1093/carcin/bgh146, 15044327.
51. Carpenter PM, Gatanaga T, Nguyen HP, Hiserodt JC. Lymphocyte and monocyte-induced motility of MCF-7 cells by tumor necrosis factor-alpha. Int J Cancer 1997, 71(1):64-70. 10.1002/(SICI)1097-0215(19970328)71:1<64::AID-IJC12>3.0.CO;2-9, 9096667.
52. Varela LM, Stangle-Castor NC, Shoemaker SF, Shea-Eaton WK, Ip MM. TNFalpha induces NFkappaB/p50 in association with the growth and morphogenesis of normal and transformed rat mammary epithelial cells. J Cell Physiol 2001, 188(1):120-131. 10.1002/jcp.1103, 11382928.
53. Warren MA, Shoemaker SF, Shealy DJ, Bshar W, Ip MM. Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice. Mol Cancer Ther 2009, 8(9):2655-2663. 10.1158/1535-7163.MCT-09-0358, 19755514.
54. Pantschenko AG, Pushkar I, Miller LJ, Wang YP, Anderson K, Peled Z, Kurtzman SH, Kreutzer DL. In vitro demonstration of breast cancer tumor cell sub-populations based on interleukin-1/tumor necrosis factor induction of interleukin-8 expression. Oncol Rep 2003, 10(4):1011-1017.
55. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC, Furcht LT. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 2001, 158(2):639-646. 10.1016/S0002-9440(10)64005-9, 1850317, 11159200.
56. Nozaki S, Sledge GW, Nakshatri H. Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun 2000, 275(1):60-62. 10.1006/bbrc.2000.3241, 10944441.
57. Palmieri C, Roberts-Clark D, Assadi-Sabet A, Coope RC, O'Hare M, Sunters A, Hanby A, Slade MJ, Gomm JJ, Lam EW, et al. Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells. J Endocrinol 2003, 177(1):65-81. 10.1677/joe.0.1770065, 12697038.
58. Verhasselt B, Van Damme J, van Larebeke N, Put W, Bracke M, De Potter C, Mareel M. Interleukin-1 is a motility factor for human breast carcinoma cells in vitro: additive effect with interleukin-6. Eur J Cell Biol 1992, 59(2):449-457.
59. Reed JR, Leon RP, Hall MK, Schwertfeger KL. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res 2009, 11(2):R21. 10.1186/bcr2246, 2688950, 19393083.
60. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9(5):361-371. 10.1038/nrc2628, 19343034.
61. Bertazza L, Mocellin S. Tumor necrosis factor (TNF) biology and cell death. Front Biosci 2008, 13:2736-2743. 10.2741/2881, 17981749.
62. Page DL. Breast lesions, pathology and cancer risk. Breast J 2004, 10(Suppl 1):S3-4. 10.1111/j.1524-4741.2004.101S2.x, 14984480.
63. Cuzick J. Treatment of DCIS--results from clinical trials. Surg Oncol 2003, 12(4):213-219. 10.1016/j.suronc.2003.09.001, 14998562.
64. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004, 96(12):906-920. 10.1093/jnci/djh164, 15199110.
65. Neumark E, Cohn MA, Lukanidin E, Witz IP, Ben-Baruch A. Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. Immunol Lett 2002, 82(1-2):111-121. 10.1016/S0165-2478(02)00026-3, 12008042.
66. Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP. Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer 2003, 106(6):879-886. 10.1002/ijc.11337, 12918065.
67. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002, 62(4):1093-1102.
68. Ali S, Kaur J, Patel KD. Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol 2000, 157(1):313-321. 10.1016/S0002-9440(10)64542-7, 1850201, 10880401.
69. Seeger H, Wallwiener D, Mueck AO. Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. Gynecol Endocrinol 2008, 24(10):576-579. 10.1080/09513590802288267, 19012101.
70. Kelly RW, Carr GG, Riley SC. The inhibition of synthesis of a beta-chemokine, monocyte chemotactic protein-1 (MCP-1) by progesterone. Biochem Biophys Res Commun 1997, 239(2):557-561. 10.1006/bbrc.1997.7502, 9344869.
71. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9(4):265-273. 10.1038/nrc2620, 19262571.
72. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009, 14(1):29-43. 10.1007/s10911-009-9110-3, 19242781.
73. Vincent-Salomon A, Thiery JP. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 2003, 5(2):101-106. 10.1186/bcr578, 154156, 12631389.
74. Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N. Expression profiling of epithelial plasticity in tumor progression. Oncogene 2003, 22(46):7155-7169. 10.1038/sj.onc.1206887, 14562044.
75. Prindull G. Hypothesis: cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells?. Exp Hematol 2005, 33(7):738-746. 10.1016/j.exphem.2005.03.002, 15963849.
76. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, Thompson EW. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 2008, 25(6):629-642. 10.1007/s10585-008-9170-6, 18461285.
77. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol 2007, 213(2):374-383. 10.1002/jcp.21223, 17680632.
78. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003, 22(2):256-265. 10.1038/sj.onc.1206113, 2034407, 12527894.
79. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001, 7(7):2076-2084.
80. Walsh MD, Luckie SM, Cummings MC, Antalis TM, McGuckin MA. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res Treat 1999, 58(3):255-266. 10.1023/A:1006345301364, 10718487.
81. Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G, Camussi G. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 2000, 157(5):1713-1725. 10.1016/S0002-9440(10)64808-0, 1885724, 11073830.
82. Line BR, Feustel PJ, Festin SM, Andersen TT, Dansereau RN, Lukasiewicz RL, Zhu S, Bennett JA. Scintigraphic detection of breast cancer xenografts with Tc-99m natural and recombinant human alpha-fetoprotein. Cancer Biother Radiopharm 1999, 14(6):485-494. 10.1089/cbr.1999.14.485, 10850335.
83. Fan F, Stoeltzing O, Liu W, McCarty MF, Jung YD, Reinmuth N, Ellis LM. Interleukin-1beta regulates angiopoietin-1 expression in human endothelial cells. Cancer Res 2004, 64(9):3186-3190. 10.1158/0008-5472.CAN-03-0407, 15126358.
84. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006, 25(3):387-408. 10.1007/s10555-006-9004-4, 17043764.